M&A Deal Summary

Kite Pharma Acquires Cell Design Labs

On December 7, 2017, Kite Pharma acquired life science company Cell Design Labs for 567M USD

Acquisition Highlights
  • This is Kite Pharma’s 2nd transaction in the Life Science sector.
  • This is Kite Pharma’s largest (disclosed) transaction.
  • This is Kite Pharma’s 1st transaction in the United States.
  • This is Kite Pharma’s 1st transaction in California.

M&A Deal Summary
Date 2017-12-07
Target Cell Design Labs
Sector Life Science
Buyer(s) Kite Pharma
Deal Type Add-on Acquisition
Deal Value 567M USD
Advisor(s) Citigroup Investment Banking (Financial)

Target

Cell Design Labs

Emeryville, California, United States
Cell Design Labs, Inc. is a biotherapeutics company pioneering breakthrough science to develop disruptive therapies for cancer and other devastating diseases. Cell Design Labs, Inc. was founded in 2015 and is based in San Emeryville, California.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kite Pharma

Santa Monica, California, United States
Category Company
Founded 2009
Sector Life Science
Employees184
Revenue 22M USD (2016)
DESCRIPTION
Kite Pharma's corporate headquarters in Santa Monica, California.
Kite Pharma's corporate headquarters in Santa Monica, California.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Kite Pharma was formed in 2009 and is based in Santa Monica, California.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 2 of 2
State (California) 1 of 1
Country (United States) 1 of 2
Year (2017) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-17 T-Cell Factory B.V.

Netherlands

T-Cell Factory B.V. develops tumor-specific TCRs for broad application in cancer treatment based on its proprietary TCR-GENErator™ platform.

Buy €20M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-19 Kite Pharma - Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility

Gaithersburg, Maryland, United States

Kite Pharma's Neoantigen TCR Cell Therapy R&D Platform & Manufacturing Facility provides production capacity to support clinical trials.

Sell -
Mergr

Product

Company

Legal